Enhance.MD Review 2026: New Pricing, Updated Pharmacy Partners, and the Regulatory Shifts Every GLP-1 Patient Should Understand

HOUSTON, April 21, 2026 (Newswire.com) - Enhance.MD GLP-1 Complete 2026 Overview: The 4 Things to Verify Before You Enroll (Pricing, Pharmacies, Compliance, Commitment Terms)

Updated April 21, 2026. This review is based on analysis of Enhance.MD's published website, terms of service, FAQ documentation, how-it-works page, and publicly available FDA regulatory guidance. No claims made here represent personal medical advice.

If you have been researching GLP-1 telehealth programs, you already know the landscape looks nothing like it did a year ago. The compounding rules changed. The pricing structures shifted. Some platforms pivoted to brand-name medications. Others quietly disappeared. And the platform you are looking at right now - Enhance.MD - is operating in a regulatory environment that requires more homework from you than it did in 2024.

That is not a reason to walk away. It is a reason to read carefully, understand exactly what you are signing up for, and verify a few specific things before you enter a payment method.

Search interest around "Enhance.MD review," "compounded semaglutide online," and "GLP-1 telehealth programs 2026" has grown significantly as patients weigh their options in a post-shortage regulatory environment. This article addresses those questions directly using publicly available information and current regulatory context - so you can make a decision based on facts, not marketing.

View the current Enhance.MD offer (official Enhance.MD page)

This guide covers all of it. What Enhance.MD actually is, how the three-party clinical structure works, what the compounding regulatory picture looks like right now, what each program costs over a full year with the real math laid out, how it stacks up against the main alternatives, and a plain-language checklist of what to confirm before you enroll. No manufactured urgency, no outcome guarantees dressed up as editorial. Just the information you need to make a decision that fits your situation.

What Enhance.MD Is and How the Clinical Structure Works

Enhance.MD is a telehealth platform that coordinates access to prescription GLP-1 weight management programs. You are not buying medication off a shelf. You are accessing a service that connects you with licensed, independent medical providers who review your health information and decide whether a prescription is clinically appropriate.

The company's own terms of service are clear on the most important structural point: Enhance.MD LLC is not a healthcare provider. According to those terms, it provides administrative and operational support to the independent medical professionals involved in care. It does not practice medicine, does not employ clinicians, and does not make prescribing decisions. Paying for access does not guarantee a prescription.

Three separate parties are involved, and understanding who does what matters before you commit any money.

Enhance.MD LLC functions as the telehealth platform facilitating connections between patients and healthcare providers. According to the platform's terms of use, Enhance.MD itself is not a healthcare provider. The platform provides the technology infrastructure, customer service, and coordination that enables the telehealth experience.

Licensed Medical Providers are independent healthcare professionals associated with affiliated medical groups - Enhance Wellness PC, EnhanceMD CA PC, and iThriveMD PC, per the company's published terms. These are the clinicians who review your intake form, evaluate your lab results, and make the prescribing decision. The platform cannot override their judgment and does not attempt to. No individual is guaranteed a prescription, as that determination rests entirely with the evaluating clinician.

Partner Pharmacies fulfill prescriptions written by the medical providers. According to the company's terms of service, current pharmacy partners include Rite-Away Pharmacy in San Antonio, Texas; Vios Compounding Pharmacy in Livonia, Michigan; and TruMedsRx in Fairfax, Virginia. These are licensed pharmacies that compound and dispense medications according to the prescriptions they receive.

This three-entity structure is standard across telehealth platforms and ensures appropriate separation between the technology platform, clinical decision-making, and medication dispensing. It is worth understanding because it shapes what you are actually evaluating: a platform that facilitates access, not a clinic that treats you directly.

The Compounding Regulatory Picture Right Now

This section matters regardless of which GLP-1 telehealth platform you are considering. Get comfortable with it before you make any decision about any provider.

The GLP-1 medications available through Enhance.MD are compounded prescription medications prepared by licensed pharmacies based on individual prescriptions. Compounded medications are not reviewed or approved by the FDA as finished products. According to the company's own product pages, these formulations are compounded in accordance with federal Section 503A guidelines. The FDA has not verified their safety or effectiveness as finished products.

The regulatory environment around compounded GLP-1 medications has tightened significantly since late 2024. The FDA removed tirzepatide from its drug shortage list in December 2024, following a declaratory order affirming that manufacturer supply was meeting demand. The FDA had previously removed semaglutide from the shortage list in February 2025. Both decisions changed the legal basis that had allowed large-scale compounding under shortage-era rules.

The broad shortage-era access that allowed large-scale compounding of both active ingredients has been significantly restricted, and current pathways are narrower and more dependent on individual prescription justification. That said, the full picture is genuinely contested. Multiple industry groups challenged the FDA's shortage determinations in federal court, and ongoing legal proceedings have created a complex regulatory environment where compounding continues through some pathways while enforcement actions proceed against others. As of April 2026, compounded semaglutide and tirzepatide remain available through some 503A and 503B compounding channels, though the regulatory and legal landscape continues to evolve.

What this means practically: any compounded GLP-1 program - including Enhance.MD - should be verified for current compliance status with the platform and its pharmacy partner before you enroll. The platform you are reviewing today should be able to tell you the specific legal basis under which its compounding pharmacy is currently operating. Readers are encouraged to verify all program details directly with the platform, the dispensing pharmacy, and a licensed healthcare provider before making a decision. This is not a replacement for prescribed medical treatment for any condition.

View the current Enhance.MD offer (official Enhance.MD page)

Four Things to Verify Before You Enroll

You can read every review on the internet, compare pricing across a dozen platforms, and still end up in a difficult situation if you skip the due diligence that actually matters. These four checks take minutes and can save you months of frustration.

1. Confirm current medication availability in your state.

According to the company's FAQ, Enhance.MD is currently available in a limited number of states and Washington D.C. Your state should be on the current list before you invest time in the intake form. Verify the current state list directly at enhance.md before starting.

2. Ask for the name and license status of the dispensing pharmacy.

According to the company's terms of service, current pharmacy partners include Rite-Away Pharmacy, Vios Compounding Pharmacy, and TruMedsRx. Because pharmacy partnerships can change, confirm which pharmacy will be filling your specific prescription before enrolling.

3. Read the full subscription, commitment, and cancellation terms before you pay.

According to the company's terms of service, the subscription auto-renews unless canceled before the next billing cycle. The commitment terms attached to promotional first-month pricing determine your actual total obligation. These details are on the checkout page - and they are worth reading carefully before you enter a card number.

4. Talk to your current healthcare provider.

GLP-1 therapy interacts with other medications, has contraindications, and involves a titration schedule that benefits from clinical oversight by someone who knows your full history. This conversation belongs before enrollment, not after. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician's guidance and approval.

You may also want to confirm medication storage and shipping requirements with the platform, particularly for temperature-sensitive injectable products.

The Science Behind Semaglutide and Tirzepatide

To evaluate any GLP-1 program well, it helps to understand what these active ingredients actually do - separately from any claims about the finished compounded products that use them.

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone naturally released in the gut in response to eating. It stimulates insulin secretion, reduces glucagon production, slows gastric emptying, and acts on areas of the brain involved in appetite and the feeling of fullness. Semaglutide has been in clinical use for over fifteen years, originally developed for type 2 diabetes management. Certain FDA-approved semaglutide formulations are also approved for chronic weight management in adults who meet specific BMI criteria.

In the STEP-1 clinical trial, participants using injectable semaglutide at 2.4mg weekly achieved an average body weight reduction of approximately 14.9 percent at 68 weeks, compared to about 2.4 percent with placebo. This is data from the FDA-approved formulation in controlled trial conditions. It is not a prediction of what any individual patient will experience, and it does not represent expected outcomes from any compounded product.

Tirzepatide activates both GLP-1 and GIP receptors simultaneously. GIP (glucose-dependent insulinotropic polypeptide) influences insulin response and fat metabolism through mechanisms that are distinct from GLP-1. This dual-agonist approach is the clinical rationale behind tirzepatide's development and approval.

In the SURMOUNT-1 trial, participants using tirzepatide achieved an average body weight reduction of approximately 20.9 percent at 72 weeks, compared to approximately 3.1 percent with placebo. The dual mechanism appears to produce meaningfully greater average weight reduction than GLP-1 monotherapy in trial settings. Individual results vary considerably.

The practical distinction for program selection comes down to mechanism. If you have been on a GLP-1 program and have plateaued, or if a clinician has suggested that stronger appetite modulation may be appropriate, tirzepatide's additional GIP activation offers a different pharmacological profile. Your evaluating clinician - not this article and not the platform - is the right person to help determine which approach fits your specific situation.

This ingredient-level data describes the FDA-approved formulations studied in clinical trials. It does not transfer directly to any compounded product, which has not undergone the same FDA finished-product review. These individual findings do not mean any compounded product replaces prescribed treatment.

View the current Enhance.MD offer (official Enhance.MD page)

Enhance.MD's Programs: What Each One Includes and What It Costs

According to the official Enhance.MD website, multiple programs are currently available. All pricing below is attributed to the company and is subject to change. According to the company's website, promotional discounts are currently available - $50 off one-month plans or $100 off multi-month plans, with no code required. Verify current pricing, promotional terms, and all commitment details at enhance.md before enrolling.

GLP-1 Core - Compounded Semaglutide

According to the brand, this program targets the GLP-1 receptor to help regulate appetite, slow gastric emptying, and support healthy glucose levels. The company positions it for first-time patients or those with moderate weight management goals. Per the brand's website, the 12-month commitment pricing starts at $112 for the first month, with $212 per month at all dose levels thereafter. Six-month commitment pricing starts at $124 for the first month and $224 per month after. Three-month starts at $137 for the first month and $237 per month after. One-month pricing is $199 for the first month and $249 per month after. According to the brand, each monthly supply includes four weeks of medication, ongoing provider care, and metabolic lab testing every six months.

GLP-1 Advanced - Compounded Tirzepatide

According to the brand, this program adds GIP receptor activation alongside GLP-1. The company describes it as helpful for patients who have plateaued on GLP-1 alone or who want stronger appetite modulation. Per the brand's website, 12-month commitment pricing starts at $180 for the first month, with $280 per month thereafter. Six-month pricing starts at $196 for the first month and $296 per month after. Three-month starts at $213 for the first month and $313 per month after. One-month pricing is $279 for the first month and $329 per month after.

GLP-1 Elite - Compounded Semaglutide and Tirzepatide

According to the brand, this program combines both compounds to engage both receptor pathways simultaneously. The company positions it for patients seeking broader metabolic engagement or those who have plateaued on other GLP-1 medication. Per the brand's website, 12-month commitment pricing starts at $222 for the first month, with $322 per month thereafter. Six-month starts at $241 for the first month and $341 per month after. Three-month starts at $260 for the first month and $360 per month after. One-month pricing is $329 for the first month and $379 per month after.

GLP-1+GIP Microdosing - Low-Dose Compounded Tirzepatide

According to the brand, this program uses dual GLP-1 and GIP signaling at a lower dose and is designed for long-term metabolic health and resilience rather than acute weight loss. The company describes the goals as supporting steady energy, cognitive clarity, and metabolic regulation while minimizing side effects, and notes that weight loss may occur but is not the primary aim. Verify current pricing and availability for this program directly at enhance.md.

NAD+ Therapy - Injectable and Wafer Options

This program is described by the brand as supporting cellular energy-related processes. The company states it is intended to raise NAD+ levels in the context of mitochondrial function and energy production. Per the brand's website, injectable NAD+ pricing ranges from $169 per month on a 12-month plan to $199 per month on a one-month plan. The company also offers NAD+ Wafers as a sublingual option, with pricing ranging from $84 per month on a 12-month plan to $99 per month on a one-month plan. Ongoing provider care is included with both options, per the brand. These descriptions are based on the brand's positioning and have not been evaluated as FDA-approved therapeutic claims.

The Same-Price-at-Every-Dose Model

According to the company's website, Enhance.MD's monthly rate does not increase as the prescribed dose increases through the titration schedule. GLP-1 titration involves gradual dose escalation over months, and platforms that price per dose level can add considerably to the total program cost. This flat-rate structure is uncommon in the category. Verify that it applies to your specific program and review current commitment terms before enrolling.

The Honest 12-Month Math

For the GLP-1 Core program on the 12-month commitment: the $112 first-month rate followed by $212 per month for the remaining 11 months brings a full 12-month total to approximately $2,444 based on published pricing. For the GLP-1 Advanced program on the 12-month commitment: first month at $180, then $280 per month, brings a 12-month total to approximately $3,260 based on published pricing. These figures assume promotional rates apply and pricing does not change. Verify all commitment terms and what is included at checkout.

For context, brand-name GLP-1 medications without insurance have generally ranged from $900 to over $1,300 per month based on publicly available market pricing. The cost difference between compounded programs and brand-name options is a significant factor driving demand for telehealth platforms in this category.

View the current Enhance.MD offer (official Enhance.MD page)

How the Process Works, Step by Step

According to the Enhance.MD website, enrollment follows four steps.

Medical Intake is an online health history form covering your medical background, current medications, and health goals. According to the company's how-it-works page, this step does not incur additional charges.

Lab Tests come next. According to the company's how-it-works page, Enhance.MD arranges baseline blood work at a nearby Quest Diagnostics facility. The panel includes a Comprehensive Metabolic Panel, Thyroid-Stimulating Hormone, Lipid panel, and Hemoglobin A1c. The company recommends fasting before the labs.

Virtual Visit is a telehealth consultation with a licensed medical provider from one of the affiliated medical groups. The provider reviews your intake and lab results and determines whether prescription therapy is appropriate. Per the company's terms, this determination rests entirely with the clinician.

Monthly Delivery follows a prescription. According to the company, the pharmacy partner fills and ships the medication to your door with free shipping included.

Before submitting the intake form, review the consent language on the platform. Per the terms, submitting your information authorizes follow-up contact including automated messages. The subscription auto-renews unless canceled before the next billing cycle. Read the cancellation terms before you pay.

How Enhance.MD Compares to the Main Alternatives

Understanding where Enhance.MD fits in the GLP-1 telehealth landscape requires looking at how the major alternatives approach the same set of challenges. This is not a substitute for your own research into each platform.

Enhance.MD vs. Hims and Hers

Hims and Hers built a significant presence in the GLP-1 space around compounded semaglutide programs, but has shifted considerably toward FDA-approved brand-name medications following regulatory changes, including a direct partnership with Novo Nordisk. Brand-name options on that platform carry higher price points. Enhance.MD is positioned around compounded formulations with published pricing structures that differ from platforms focused on FDA-approved medications. Patients who specifically want FDA-approved finished products will find Hims and Hers or a traditional provider more aligned with that requirement. Patients evaluating compounded programs with flat-rate pricing and lab work included are comparing against what Enhance.MD offers.

Enhance.MD vs. Noom Med

Noom Med combines GLP-1 medication access with an integrated behavioral platform - psychology-based habit coaching, progress tracking, and structured lifestyle support built into the program. That behavioral layer is Noom's genuine differentiator. Enhance.MD focuses on the clinical and pharmacological pathway with provider oversight and lab monitoring but does not include a coaching app. Neither is categorically better. The right choice depends on whether structured behavioral support matters to how you approach change.

Enhance.MD vs. Ro

Ro is one of the telehealth platforms in Novo Nordisk's partner network for FDA-approved oral Wegovy. For patients who specifically want an oral GLP-1 option, Ro's access to the Wegovy pill is a meaningful differentiator. Enhance.MD's programs are injectable and compounded.

What Sets Enhance.MD Apart, in Its Own Words

Based on publicly available information, the platform describes as differentiated: a same-price-at-every-dose flat rate across all titration levels, a tiered program structure that includes a dedicated low-dose longevity-focused option, and lab work coordinated through Quest Diagnostics built into the intake process rather than arranged separately by the patient. These are verifiable structural features, not marketing claims about outcomes.

Who Enhance.MD May Be Right For

Enhance.MD May Align Well With People Who:

Want a clinician-supervised compounded GLP-1 program at a lower price point than brand-name options. The published price gap between Enhance.MD's programs and brand-name GLP-1 medications is substantial. If cost is the primary barrier to access and you are comfortable proceeding with a compounded formulation under clinical oversight, the platform's structure addresses that combination.

Have a BMI of 25 or higher and have not found lasting results through conventional approaches. Per the company's FAQ, new patients require a BMI of 25 or higher. For people who have made real attempts at conventional weight management without maintaining results, a GLP-1 program represents a pharmacologically distinct approach that works through different mechanisms than diet and exercise alone.

Prefer a telehealth-only model and are comfortable with self-administered weekly injections. The entire Enhance.MD process is remote. If you prefer managing this without in-person visits and can follow injection technique guidance from a provider, the platform's structure fits that preference.

Have prior GLP-1 experience and want a low-dose maintenance protocol focused on long-term metabolic health. The Microdosing Tirzepatide program is a specifically developed option for patients who are not in active weight-loss mode but want to sustain metabolic health at lower doses. Very few telehealth platforms offer this as a named, structured program.

Other Options May Be Preferable For People Who:

Want FDA-approved finished drug products. Enhance.MD's programs involve compounded medications that have not undergone the same FDA finished-product review as brand-name drugs. If that level of regulatory review is a requirement for you, brand-name GLP-1 options through traditional providers or platforms like Ro are more aligned with that need.

Want behavioral coaching integrated into the program. Enhance.MD focuses on the clinical pathway. Noom Med includes integrated psychology-based coaching. If that layer is part of how you succeed with lasting change, a platform that offers it may serve you better.

Need immediate access without a lab work requirement. Enhance.MD requires baseline labs through Quest Diagnostics before prescribing, which adds time to the onboarding process. Some platforms skip this step. Whether that is a benefit or a drawback depends on how you prioritize speed versus clinical thoroughness.

Are in a state where the platform is not currently active. Confirm your state on the FAQ page at enhance.md before starting.

Need to use insurance, FSA, or HSA funds. Per the company's FAQ, FSA and HSA cards are currently not accepted. The service operates on a cash-pay basis. Verify current payment policies before enrolling.

This type of program may also not be appropriate for individuals uncomfortable with compounded formulations or those requiring insurance-based coverage for their GLP-1 therapy.

Questions to Ask Yourself Before Enrolling

Is your BMI within the qualifying threshold? Is your state on the current availability list? Do you understand the difference between a compounded medication and an FDA-approved drug, and are you comfortable proceeding? Have you reviewed the subscription, auto-renewal, and cancellation terms? Have you spoken with your current healthcare provider about whether a GLP-1 program is appropriate given your full medical history and medications?

Your honest answers to those five questions are more valuable than any review in determining whether this is the right next step for you.

Safety: What to Understand Before You Start

This is a high-level overview and does not replace the patient education materials that come with your prescription. The following points are not a complete list of risks or precautions.

Gastrointestinal adjustment effects are the most commonly reported experience during GLP-1 dose escalation. Nausea, reduced appetite, constipation, and occasional vomiting are documented in clinical literature, particularly in the early weeks at each new dose level. These effects typically ease as the body adjusts. Individual tolerance varies considerably.

Contraindications requiring clinical screening include personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, among other conditions. The intake form and evaluating clinician screen for these - which is one reason an honest and complete health history matters.

Drug interactions are relevant if you take medications that affect blood sugar, blood pressure, or weight. Disclose your full medication list during intake. Starting GLP-1 therapy without your prescribing clinician knowing everything you take is not a safe approach.

Pregnancy and nursing are generally contraindications. Disclose if you are pregnant, planning pregnancy, or nursing.

Age. According to the company's terms, the service is intended for adults 18 and older.

This is not a substitute for prescribed medical treatment for any condition. This overview is not exhaustive and does not replace the patient education provided with your prescription. Always consult your physician before starting, especially if you have existing conditions or take other medications. Do not change, adjust, or discontinue any medications without your physician's guidance.

Final Assessment: What the Evidence Shows

Based on the company's published website materials, Enhance.MD appears to be an operating telehealth platform that connects eligible patients with licensed independent medical providers and compounding pharmacy partners. Its terms of service are transparent about the platform's non-provider status. Its pricing is published. Its affiliated medical groups are named. Its pharmacy partners are identified in its terms of service. Its contact information and addresses are verifiable. These are the markers of a functioning, accountable platform.

The platform describes as differentiated a same-price-at-every-dose model across all titration levels, a tiered compounded GLP-1 lineup that includes a named low-dose longevity program, and lab work coordinated through Quest Diagnostics built into the intake process. Those are concrete structural claims that can be verified before you enroll.

The Case for Enhance.MD: Published pricing is meaningfully below brand-name GLP-1 options, the flat-rate dose structure removes cost uncertainty during titration, the three-entity clinical structure provides appropriate separation between platform, provider, and pharmacy, and the inclusion of lab work and ongoing provider care distinguishes the platform from less comprehensive options in this space. The tiered program lineup - from Core through Elite, plus a dedicated Microdosing option - offers more granularity than many alternatives when it comes to matching a program to individual needs.

Considerations to Weigh: These are compounded medications, not FDA-approved finished drug products. The regulatory environment for compounded GLP-1 medications has tightened significantly and remains in flux. The subscription auto-renews, and commitment terms attached to promotional pricing affect your total obligation. FSA and HSA are not currently accepted per the company's FAQ. And as with any telehealth platform, the quality of care depends on the individual clinician assigned to your case. Any results referenced in the brand's own materials are self-reported and may not reflect typical outcomes.

Important Note: GLP-1 telehealth and compounded medication platforms have been subject to significant regulatory scrutiny since 2025, including FDA enforcement actions and active litigation across the industry. Patients considering any compounded GLP-1 platform should understand this context before enrolling and should independently verify the current compliance and program status directly with the platform and their own healthcare provider.

View the current Enhance.MD offer (official Enhance.MD page)

How to Get Started

The process begins with the online medical intake form at enhance.md. According to the company, this step does not incur additional charges. From there, Enhance.MD coordinates lab work at a nearby Quest Diagnostics location, per the how-it-works page. A licensed provider from one of the affiliated medical groups then reviews your intake and results and determines whether prescription therapy is appropriate.

According to the company's terms, the platform is for adults 18 and older. Per the company's FAQ, new patients require a BMI of 25 or higher. According to the company's website, if at any point during the onboarding process a provider finds you ineligible for medication, the company states it will provide a refund of your initial payment. Verify the specific terms of that commitment at enhance.md before enrolling.

Contact Information

According to the company's published contact details:

Company: Enhance.MD

Phone: 1-888-299-5088

Email: support@enhance.md

Hours: Monday through Friday, 8:00 AM to 8:00 PM EDT; Saturday and Sunday, 9:00 AM to 5:00 PM EDT

View the current Enhance.MD offer (official Enhance.MD page)

Frequently Asked Questions

Is Enhance.MD a Legitimate Platform?

Based on published information, Enhance.MD is a functioning telehealth platform with verifiable corporate addresses, published terms of service, named affiliated medical groups (Enhance Wellness PC, EnhanceMD CA PC, and iThriveMD PC), named pharmacy partners (Rite-Away Pharmacy, Vios Compounding Pharmacy, and TruMedsRx per its terms of service), customer support contact information, and a current program lineup with published pricing. The company's terms explicitly state it is not a healthcare provider and that prescribing decisions rest with independent licensed clinicians.

Are Enhance.MD's GLP-1 Medications FDA-Approved?

No. According to the company's own website, its medications are compounded and are not FDA-approved. The FDA has not verified their safety or effectiveness as finished products. According to the company's product pages, these formulations are compounded in accordance with federal Section 503A guidelines. Compounded medications are prepared by licensed pharmacies using active pharmaceutical ingredients from FDA-registered sources, based on individual prescriptions from licensed clinicians. They are not the same as FDA-approved finished drug products.

Is Compounded Tirzepatide the Same as Zepbound?

Compounded tirzepatide may use the same active pharmaceutical ingredient as FDA-approved products such as Zepbound and Mounjaro, but it differs in formulation, manufacturing process, and regulatory review status. The FDA-approved brand-name versions have been reviewed for safety, effectiveness, and quality as finished products. Compounded versions have not undergone that finished-product review.

What States Does Enhance.MD Serve?

According to the company's FAQ, Enhance.MD is currently available in a limited number of states and Washington D.C. The current state list is published on the FAQ page at enhance.md. Confirm your state directly before starting the intake process.

Does Insurance Cover Enhance.MD?

Enhance.MD operates on a cash-pay basis per its terms. According to the company's terms of service, services are provided on a cash-pay basis and are not billable to federal or state healthcare programs such as Medicare or Medicaid. Most traditional insurance plans do not cover direct-to-consumer compounded programs. Per the company's FAQ, FSA and HSA cards are not currently accepted. Coverage policies vary. Always confirm directly with your insurer and Enhance.MD before enrolling.

What Is the Difference Between the Core, Advanced, and Elite Programs?

According to the company: Core uses compounded semaglutide and engages the GLP-1 receptor. Advanced uses compounded tirzepatide and engages both GLP-1 and GIP receptors. Elite combines both compounds to engage both receptor pathways. The evaluating clinician determines which program, if any, is appropriate for your situation.

Can I Cancel Enhance.MD?

According to the company's terms of service, the subscription auto-renews unless canceled before the next billing cycle. Full subscription and cancellation terms are provided at checkout. Review these carefully before paying. Per the brand's website, if a provider determines you are ineligible during the onboarding process, the company states it will provide a refund. Verify the specific terms of that commitment at enhance.md.

How Does Enhance.MD Handle Lab Work?

According to the company's how-it-works page, Enhance.MD arranges baseline blood work at a nearby Quest Diagnostics facility as part of the intake process. The panel covers Comprehensive Metabolic Panel, Thyroid-Stimulating Hormone, Lipid panel, and Hemoglobin A1c. The company recommends fasting before the labs. Ongoing metabolic lab testing every six months is included in the GLP-1 programs, per the brand.

How Does Enhance.MD Compare to Hims and Hers for GLP-1?

Hims and Hers has shifted toward FDA-approved brand-name GLP-1 options following regulatory changes affecting compounded semaglutide, including a direct partnership with Novo Nordisk for Wegovy. Enhance.MD is positioned around compounded formulations with different published price points. The choice comes down to whether you want an FDA-approved finished product - where Hims and Hers or a traditional provider fits - or a compounded program under clinician oversight with a different pricing structure, where Enhance.MD's model is more relevant.

Is GLP-1 Compounding Still Available in 2026?

This is one of the most searched questions in the category right now, and the honest answer is: it is complicated. The FDA removed tirzepatide from its shortage list in December 2024 and semaglutide in February 2025, which ended the shortage-based legal justification for large-scale compounding of both active ingredients. However, ongoing legal challenges from industry groups have created injunctions and regulatory uncertainty that have prevented a complete shutdown. As of April 2026, compounding continues through some 503A and 503B pathways, but the environment is under active regulatory and legal scrutiny. Any platform currently offering compounded GLP-1 programs should be asked directly about the specific legal basis under which its pharmacy partners are operating before you enroll.

Disclaimers

Content and Medical Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. The descriptions of potential benefits are not guarantees and are not substitutes for an individualized medical evaluation. Enhance.MD's programs involve compounded prescription medications that require evaluation and prescription by a licensed clinician. The information here does not replace the professional judgment of your healthcare provider.

Professional Medical Disclaimer: This article is educational and does not constitute medical advice. Compounded GLP-1 medications are not a substitute for prescribed medical treatment for any condition. If you take other medications, have existing health conditions, are pregnant or nursing, or are considering changes to your health regimen, consult your physician before starting any new prescription treatment. Do not change or discontinue any medications without your physician's guidance.

Compounded Medication Notice: The GLP-1 medications available through Enhance.MD are compounded prescription medications prepared by licensed pharmacies based on individual prescriptions. Compounded medications are not reviewed or approved by the FDA as finished products. They are not the same as FDA-approved generics or brand-name drugs. The FDA does not verify the safety, effectiveness, or quality of compounded drugs in the same manner it reviews approved drugs. According to the company's product pages, these formulations are compounded in accordance with federal Section 503A guidelines.

Regulatory Environment Notice: The compounded GLP-1 medication space is under active regulatory scrutiny and ongoing litigation as of the date of this article. The FDA declared both tirzepatide and semaglutide injection shortages resolved in late 2024 and early 2025, respectively, which changed the shortage-based compounding framework. Ongoing legal proceedings have created uncertainty about enforcement. Patients should verify the current compliance status of any compounded GLP-1 program directly with the platform and their healthcare provider before enrolling.

Results May Vary: Individual results will vary based on factors including age, baseline health condition, starting weight, adherence to the prescribed protocol, lifestyle factors, medication consistency, genetic factors, current medications, and other individual variables. Results are not guaranteed.

FTC Affiliate Disclosure: This article contains affiliate links. If you pursue the program through those links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All descriptions are based on publicly available information from the company's official website and published regulatory sources.

Pricing Disclaimer: All prices and promotional offers mentioned were based on publicly available information at the time of research, April 2026, and are subject to change without notice. Promotional first-month rates are subject to commitment terms and new-customer eligibility requirements per the brand's current policies. Always verify current pricing directly at enhance.md before enrolling.

Publisher Responsibility: The publisher has made every effort to ensure accuracy at the time of publication based on publicly available information. We do not accept responsibility for errors, omissions, or outcomes resulting from the use of this information. Readers are encouraged to verify all details directly with Enhance.MD and their healthcare provider before making decisions.

Insurance Coverage Note: Enhance.MD operates on a cash-pay basis per its terms. According to the company's terms of service, services are not billable to federal or state healthcare programs. Most direct-to-consumer compounded prescription programs are not covered by traditional insurance plans. Per the company's FAQ, FSA and HSA cards are not currently accepted. Coverage policies vary. Always confirm directly with your insurer and Enhance.MD before enrolling.

SOURCE: Enhance.MD

Source: Enhance.MD